steer study semaglutide 👨‍🔬 2025年8 月#ESC 發表的#真實世界研究- #STEER study，顯示semaglutide 相較於tirzepatide，在#無糖尿病但有#ASCVD的體重過重/ #肥胖患者中，觀察到#顯著降低57% 的

Wegovy® Demonstrates Superior Cardiovascular Benefit Over Tirzepatide in Real-World Study

22.35

★★★★☆4.8 (126)

STEER_SCORE trial for the use of semaglutidepptx

22.97

★★★★★4.9 (98)

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial

20.32

★★★★★5.0 (157)

SEMAGLUTIDE vs TIRZEPATIDE 2⃣drugs 2⃣different trial design 2⃣different results Take on account doses, populations, endpoints, follow-up, 📌STEER-Overweight/obesity & ASCVD with/without DM 📌SURMOUNT-5 Obesity without DM or ASCVD #ESCCongress

23.76

★★★★★4.7 (84)

SEMAGLUTIDE vs TIRZEPATIDE 2⃣drugs 2⃣different trial design 2⃣different results Take on account doses, populations, endpoints, follow-up, 📌STEER-Overweight/obesity & ASCVD with/without DM 📌SURMOUNT-5 Obesity without DM or ASCVD #ESCCongress

27.50

★★★★★4.9 (203)

Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial

28.75

★★★★★5.0 (176)

Semaglutide may reduce heart events more than tirzepatide

24.12

★★★★★4.8 (132)